

## EFFICACY AND SAFETY OF EVOLOCUMAB IN HYPERCHOLESTEROLAEMIA AND MIXED DYSLIPIDAEMIA

Cancela-Díez B.<sup>1</sup>, Muñoz C.<sup>1</sup>, Claramunt R.<sup>1</sup>, Guijarro S.<sup>2</sup>, Barbero MJ<sup>1</sup>, Horno F.<sup>1</sup>

<sup>1</sup>Complejo Hospitalario de Jaén, Pharmacy, Jaén, Spain.

<sup>2</sup>Complejo Hospitalario Universitario de Granada, Pharmacy, Granada, Spain

**OBJETIVE:** To describe the efficacy and safety of evolocumab in patients who are affected by hipercholesterolemia and mixed dyslipemia.

**METHODS:** Retrospective observational study in which it was tested the efficacy and safety of evolocumab by means of revising the medical records of patients who received evolocumab during 2016 and until May 2017.

To test the efficacy we measured the percentage of cholesterol reduction LDL (C-LDL) 12 weeks after the start of this therapy.

To test safety we revised the adverse events derived from evolocumab seen in the medical record of the patient.

### RESULTS:

|   |                                    |                      |
|---|------------------------------------|----------------------|
| Sex   | 22 males/8 females                 |                      |
| Diagnostic                                    | Familiar hypercholesterolaemia 30% |                      |
|   | Mixed dyslipaemia 86%              |                      |
| Previous treatment                            | Statins 86%                        |                      |
|   | Fibrates 20%                       |                      |
|   | Ezetimibe 83%                      |                      |
| Evolocumab dosage                             | 140 mg/30 days                     |                      |
| Average reduction C-LDL week 12 (%)           | 63%                                |                      |
| Percentage of patients with any adverse event | 12%                                | Myalgia 3%           |
|   |                                    | Arthralgia 3%        |
|   |                                    | Diarrhoea 3%         |
|   |                                    | Gingival bleeding 3% |

### DISCUSSION/CONCLUSIONS:

Evolocumab is an effective drug to reduce C-LDL level. However further studies are needed to demonstrate the reduction of mortality in patients with high cardiovascular risk. Evolocumab has proved to be a safe medicament.